Catalio Capital Management

About The Fund

Catalio Capital Management, based in Baltimore, Maryland, is a multi-strategy investment firm that specializes in identifying and investing in breakthrough biomedical technology companies. The firm's investment scope covers innovative healthcare companies worldwide, spanning various sub-sectors such as innovative drugs, medical devices, diagnostics, data, tools, and healthcare services. Catalio's investment strategies include a flagship private equity strategy that focuses on privately held companies at all stages, from seed to crossover. They also provide structured opportunities through their private credit strategy, offering senior-secured financing to companies. Their public equities strategy entails a long-bias, fundamental, bottoms-up equity long/short strategy investing across global healthcare equities. Furthermore, Catalio supports co-investment vehicles, giving their Limited Partners direct access to their prime deals. Founded in 2020 by George Petrocheilos and R. Jacob Vogelstein, Catalio aims to generate extraordinary returns by creating and maintaining life sciences companies that excel in science, technology, management, and execution. Their approach involves collaborating with Catalio Venture Partners—an elite cadre of the world's finest scientists, engineers, and clinicians—to spot and invest in groundbreaking biotechnologies, co-invest alongside top-tier funds, and draw A-list talent from their extensive networks. Deeply involved with each portfolio company, Catalio strives to nurture and expand the business from its inception to exit. Their investment expertise is complemented by the synergistic efforts of their team of investment professionals and world-renowned, serial scientist-entrepreneurs, recognized for their successful track record in launching and spinning out top-tier businesses within the life sciences sector.